In the block group, the 125I-anti-TLR5 mAb uptake of TLR5+ 4T1 tumor was only 1.67 ± 0.14 %ID/g at 48 h, suggesting that 125I-antiTLR5 binding with tumor was blocked by unlabeled anti-TLR5 mAb pre-injection in vivo. The gene discussed is TLR5; the disease is neoplasm.